Trenkwalder 2017.

Methods	Randomised, placebo‐controlled trial
Participants	110 participants with at least moderately severe RLS (IRLS >= 15) and serum ferritin less than 75 ng/mL (or serum ferritin 75‐300 ng/mL and transferrin saturation < 20%)
Interventions	Intervention: intravenous ferric carboxymaltose, 1000 mg infusion over 15 minutes Control: placebo with matched infusion rate
Outcomes	IRLS, CGI‐severity, PGI‐C, RLS‐6 quality of life scale, MOS sleep
Notes	Funded by pharmaceutical company
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised by statistician
Allocation concealment (selection bias)	Low risk	Central allocation
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Nurse administering treatment was not blinded but did not assess outcomes. Unclear how treatment was concealed during IV administration
Incomplete outcome data (attrition bias) All outcomes	Low risk	Relatively high dropout rate (21%), but for similar reasons and used last observation carried forward
Selective reporting (reporting bias)	Low risk	Protocol registered on EudraCT prior to start of enrolment; protocol consistent with reported outcomes
Other bias	Low risk	No other risks identified